These findings suggest that the ameliorative effect of DSS treatment on cognitive function can be attributed to the repair of metabolic disorders and the intestinal and blood–brain barriers, which might be by activating the LXR and PPAR-γ. The gene discussed is PPARG; the disease is metabolic disease.